Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT01908010 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie